696 860
Table 3 (
Continued
)
Patients
(
N
)
Pre-RT
PSA level
(median)
Technique
Concomitant
ADT
Dose
(median)
Study
period
Follow-up
(median)
Outcomes
Predictors of
response to sRT
Blanchard et al
[39]
136
0.6 ng/ml
3D-CRT to the
prostatic fossa
No
66 Gy
2002–2007 60 mo
5-yr BCR-free survival: 57%
5-yr CR-free survival: 92.5%
5-yr OS: 96.7%
PSA decline during RT
(PSA at 5 wk after
RT/PSA before RT)
Pre-RT PSA levels
Briganti et al
[40]472
0.24 ng/ml
Conventional
non-conformal
RT or 3D-CRT to
the prostatic
fossa
No
66.6 Gy
1993–2009 58 mo
5-yr BCR-free survival: 73.4%
Pathologic stage
Gleason score
Surgical margins
Pre-RT PSA levels
Fossati et al
[43]716
0.2 ng/ml
Conventional
non-conformal
RT or 3D-CRT
to the prostatic
fossa
No
66.6 Gy
1996–2009 57 mo
5-yr BCR-free survival: 82%
Pathologic stage
Gleason score
Surgical margins
Pre-RT PSA levels
Tendulkar et al
[55]2,460
0.5 ng/ml
Pelvic irradiation
in 17% of pts
16% pts
received ADT
66 Gy
1987–2013 60 mo
5-yr BCR-free survival: 56%
10-yr CR-free survival: 81%
Pre-RT PSA levels
Gleason score
Pathologic stage
Stish et al
[54]
1,160
0.6 ng/ml
3D-CRT or IMRT;
pelvic irradiation
in 4% of pts
16.4% pts
received ADT
68 Gy
1987–2013 8.9 yr
5-yr BCR-free survival: 50.1%
10-yr BCR-free survival: 35.7%
10-yr CR-free survival: 80.1%
10-yr OS: 77.3%
Pathologic stage
Gleason score
Pre-RT PSA levels
ADT
SRT dose
Fiorino et al
894
<
2 ng/ml
3D-CRT
NA
66.6 Gy
1996–2012 72 mo
5-yr BCR-free survival: 80%
Gleason score
Pre-RT PSA levels
Dose
Overall
[58]NA
0.2-0.8 ng/ml
3D-CRT or
IMRT in the
prostatic fossa
or whole pelvis
0–71%
66–76 Gy NA
3–12 yr
5-yr BCR = 50% (37–82%)
10-yr CR = 80% (80.1–81%)
Pre-RT PSA level
Pathologic characteristics
PSADT
Dose
ADT = androgen-deprivation therapy; BCR = biochemical-recurrence; CR = clinical-recurrence; CSS = cancer-specific survival; IMRT = intensity-modulated radiotherapy; NA = not applicable; OS = overall survival;
PSA = prostate specific antigen; PSADT = prostate specific antigen doubling time; pts = patients; RP = radical prostatectomy; RT = radiotherapy; 3D-CRT = three-dimensional conformal approach.
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 6 8 9 – 7 0 9
696